SUPERNUS PHARMACEUTICALS, INC. 8-K

What Happened

• Supernus Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026 by issuing a press release dated May 5, 2026. The press release is furnished as Exhibit 99.1 to the 8-K.
• The company held a conference call and live webcast to present the business and financial results on Tuesday, May 5, 2026 at 4:30 p.m. Eastern Time; the webcast is available at www.supernus.com and will be archived for 60 days.

Key Details

• Report type: Item 2.02 — Results of Operations and Financial Condition (press release furnished as Exhibit 99.1).
• Quarter reported: Quarter ended March 31, 2026; press release dated May 5, 2026.
• Earnings webcast: Live on May 5, 2026 at 4:30 p.m. ET; archived on the company website for 60 days.
• Regulatory note: The press release and related information are "furnished" (not "filed") under the Exchange Act and the 8-K includes standard forward‑looking statement disclaimers referencing risk factors in Supernus’ Form 10‑K filed March 2, 2026.

Why It Matters

• This filing signals Supernus’ official release of its Q1 2026 quarterly results and provides investors access to management commentary via the webcast.
• The 8-K does not itself include financial line items; investors should review Exhibit 99.1 (the press release) and listen to the call/webcast for revenue, earnings, and other material metrics.
• The furnishing (vs. filing) status and forward‑looking disclaimers are standard but remind investors to consider the company’s disclosed risk factors (see the March 2, 2026 Form 10‑K) when evaluating guidance or forward‑looking statements.